Ropheteq – Trademark Portfolio

Entity Type: 16

Ropheteq holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include IZOTRIS and ROPHETEQ. The owner is based in Tomball, TX.

127 West Wading Pond Cir

Tomball, TX 77375

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ROPHETEQ
ROPHETEQ
Registered 2024
IZOTRIS
IZOTRIS
Registered 2024
Trademark
Serial #98838396
Registered 2024
Trademark
Serial #98838406
Registered 2024

Trademark Classifications

Ropheteq's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Ropheteq have?

Ropheteq has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.

What trademark classes does Ropheteq file in?

Ropheteq files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Ropheteq's most well-known trademarks?

Ropheteq's registered trademark portfolio includes well-known marks such as IZOTRIS and ROPHETEQ. These are among 4 currently registered trademarks in the portfolio.

What is Ropheteq's trademark registration success rate?

Ropheteq has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.